Literature DB >> 32712768

Mapping the cancer-specific FACT-B onto the generic SF-6Dv2.

Azin Nahvijou1, Hossein Safari2, Mahmood Yousefi3, Marziyeh Rajabi4, Morteza Arab-Zozani5, Hosein Ameri6.   

Abstract

INTRODUCTION: The health-related quality of life (HRQoL) data extracted from cancer-specific questionnaires are often non-preference based, while patient preference-based utility data are required for health economic evaluation. This study aimed to map Functional Assessment of Cancer Therapy-Breast (FACT-B) subscales onto the Short Form six Dimension as an independent instrument (SF-6Dv2ind-6) using the data gathered from patients with breast cancer.
METHODS: Data for 420 inpatient and outpatient patients with breast cancer were gathered from the largest academic center for cancer patients in Iran. The OLS and Tobit models were used to predict the values of the SF-6Dv2ind-6 with regard to the FACT-B subscales. Prediction accuracy of the models was determined by calculating the root mean square error (RMSE) and mean absolute error (MAE). The relationship between the fitted and observed SF-6Dv2ind-6 values was examined using the Intraclass Correlation Coefficients (ICC). Goodness of fit of models was assessed using the predicted R2 (Pred R2) and adjusted R2 (Adj R2). A tenfold cross-validation method was used for validation of models.
RESULTS: Data of 416 patients with breast cancer were entered into final analysis. The model included main effects of FACT-B subscales, and statistically significant clinical and demographic variables were the best predictor for SF-6Dv2ind-6 (Model S3 of OLS with Adj R2 = 61.02%, Pred R2 = 59.25%, MAE = 0.0465, RMSE = 0.0621, ICC = 0.678, AIC = -831.324, BIC = -815.871).
CONCLUSION: The best algorithm developed for SF-6Dv2ind-6 enables researchers to convert cancer-specific instruments scores into preference-based scores when the data are gathered using cancer-specific instruments.

Entities:  

Keywords:  Breast cancer; FACT-B; Quality of life; SF-6Dv2

Mesh:

Year:  2020        PMID: 32712768     DOI: 10.1007/s12282-020-01141-9

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  25 in total

1.  Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.

Authors:  Jonathan C Tosh; Louise J Longworth; Elisabeth George
Journal:  Value Health       Date:  2011-01       Impact factor: 5.725

2.  Mapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights.

Authors:  Robert L Askew; Richard J Swartz; Yan Xing; Scott B Cantor; Merrick I Ross; Jeffrey E Gershenwald; J Lynn Palmer; Jeffrey E Lee; Janice N Cormier
Journal:  Value Health       Date:  2011-06-24       Impact factor: 5.725

3.  Development of Conversion Functions Mapping the FACT-B Total Score to the EQ-5D-5L Utility Value by Three Linking Methods and Comparison with the Ordinary Least Square Method.

Authors:  Chun Fan Lee; Raymond Ng; Nan Luo; Yin Bun Cheung
Journal:  Appl Health Econ Health Policy       Date:  2018-10       Impact factor: 2.561

4.  Marked increase in breast cancer incidence in young women: A 10-year study from Northern Iran, 2004-2013.

Authors:  Abdolreza Fazel; Susan Hasanpour-Heidari; Fatemeh Salamat; Siamak Rajaie; Vahideh Kazeminezhad; Mohammad Naeimi-Tabiei; Ataollah Jahangirrad; SeyedMehdi Sedaghat; Reza Hosseinpoor; Fatemeh Ghasemi-Kebria; Gholamreza Roshandel; Elisabete Weiderpass
Journal:  Cancer Epidemiol       Date:  2019-07-19       Impact factor: 2.984

5.  Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.

Authors:  Eric Q Wu; Parvez Mulani; Max H Farrell; Darryl Sleep
Journal:  Value Health       Date:  2007 Sep-Oct       Impact factor: 5.725

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping.

Authors:  Laura A Gray; Allan J Wailoo; Monica Hernandez Alava
Journal:  Value Health       Date:  2018-08-09       Impact factor: 5.725

8.  Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.

Authors:  Michela Meregaglia; Ludovica Borsoi; John Cairns; Rosanna Tarricone
Journal:  Eur J Health Econ       Date:  2017-09-25

9.  Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.

Authors:  Qing Yang; Xue Xin Yu; Wei Zhang; Hui Li
Journal:  Health Qual Life Outcomes       Date:  2019-10-15       Impact factor: 3.186

10.  Mapping the functional assessment of cancer therapy-breast (FACT-B) to the 5-level EuroQoL Group's 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population.

Authors:  Yin Bun Cheung; Nan Luo; Raymond Ng; Chun Fan Lee
Journal:  Health Qual Life Outcomes       Date:  2014-12-12       Impact factor: 3.186

View more
  1 in total

1.  Interim value set for the EQ-5D-5L in Iran using the Crosswalk method.

Authors:  Hosein Ameri; Hossein Safari; Mahmood Yousefi; Saeid Bagheri Faradonbeh; Reza Goudarzi; Moslem Soofi
Journal:  Med J Islam Repub Iran       Date:  2020-09-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.